Current reports
Current report No. 55/2021 – Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.
In connection with current report No. 13/2021 K on Celon Pharma S.A. (“Company”) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence
Current report No. 54/2021 – Signing of an agreement on implementing and co-funding a commercial clinical trial project – development of innovative therapeutic solutions using RNA technology
The Management Board of Celon Pharma S.A. (“Company”, “Beneficiary”) hereby informs that on December 13, 2021 an agreement was signed between the Company and the Medical Research Agency (“Agency”) on implementing and co-funding a commercial clinical trial project – development of innovative therapeutic solutions using RNA technology, entitled: “TransformRNA – mRNA Therapeutics generation platform” (“Agreement” and “Project” or “TransformRNA”, respectively). Information that the aforementioned project was selected for co-funding has been announced by the Company in current report No. 48/2021 on November 29, 2021.
Current report No. 53/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on December 9, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Current report No. 52/2021 – Obtaining a European patent for esketamine inhalation formulation in the treatment of treatment-resistant depression
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that the Company has been notified today that it has been granted a European patent for the use of esketamine inhalation formulation in the treatment of treatment-resistant depression.
Current report No. 51/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on December 3, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Current report No. 50/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on December 1, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Current report No. 49/2021 K – Supplement to current report 49/2021 dated November 30, 2021 concerning the change in the composition of the Management Board of Celon Pharma S.A.
November 30, 2021, hereby forwards a statement of Ms Dorota Zwolińska, appointed on November 30, 2021 by the Company’s Supervisory Board to the Management Board as of December 15, 2021.
Current report No. 49/2021 – Change in the composition of the Management Board of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (hereinafter: the “Company”) hereby informs that today it has been notified of Ms Iwona Giedronowicz’s resignation from the position of member of the Company’s Management Board. Ms Iwona Giedronowicz held the position of member of the Company’s Management Board and Chief Financial Officer since 2014.
Current report No. 48/2021 – Celon Pharma S.A.’s project on the development of innovative therapeutic solutions with the use of RNA technology is granted co-funding
The Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on November 29, 2021 it received information that the Company’s application for co-funding of the project entitled “TransformRNA – mRNA Therapeutics generation platform” (the “Project”) submitted to the competition announced by the Medical Research Agency for the commercial clinical trials entitled “Development of innovative therapeutic solutions using RNA technology” (ABM/2021/5), has been selected for co-funding.